仑伐替尼联合帕博利珠单抗治疗晚期肾细胞癌患者疗效特征:3期CLEAR研究最终预设生存分析
3期CLEAR试验中,仑伐替尼联合帕博利珠单抗(L+P)在初治晚期肾细胞癌患者中疗效优于舒尼替尼,客观缓解率达71%。本文报告L+P组在最终预设总生存分析时中位随访约4年的肿瘤缓解特征,完全缓解组中位缓解持续时间43.7个月,36个月总生存率97%。
要点
- L+P组完全缓解(n=65)中位缓解持续时间43.7个月,36个月总生存率97%。
- 近完全缓解组(n=59)中位缓解持续时间30.5个月,36个月总生存率86%。
- 其他部分缓解组(n=129)中位缓解持续时间17.2个月,36个月总生存率62%。
核心结论
- L+P的稳健缓解支持该联合方案作为晚期肾细胞癌一线标准治疗。
研究设计与样本
- 3期CLEAR试验,纳入初治晚期肾细胞癌患者,L+P组在最终预设总生存分析时中位随访约4年,肿瘤缓解由独立评审按RECIST v1.1评估。
主要发现
- 完全缓解组(n=65)中位缓解持续时间43.7个月(95%CI 39.2-不可估计),36个月总生存率97%。
- 近完全缓解组(n=59)中位缓解持续时间30.5个月(95%CI 22.4-不可估计),36个月总生存率86%。
- 其他部分缓解组(n=129)中位缓解持续时间17.2个月(95%CI 12.5-21.4),36个月总生存率62%。
- 国际转移性肾细胞癌数据库联盟 favorable-risk 亚组客观缓解率69%(95%CI 60-78%),intermediate-risk 亚组73%(95%CI 67-79%),poor-risk 亚组70%(95%CI 54-85%)。
关键数值与推荐
- 完全缓解定义为完全缓解(CR;n=65),近完全缓解定义为部分缓解且最大肿瘤缩小≥75%(n=59),其他部分缓解定义为部分缓解且最大肿瘤缩小<75%(n=129)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the phase 3 CLEAR trial, lenvatinib plus pembrolizumab (L + P) showed superior efficacy versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma (aRCC). The combination treatment was associated with a robust objective response rate of 71%. Here we report tumor responses for patients in the L + P arm in CLEAR, with median follow-up of ∼4 yr at the final prespecified overall survival (OS) analysis. Tumor responses were assessed by independent review using Response Evaluation Criteria in Solid Tumors v1.1. Patients with a complete response (CR; n = 65), partial response (PR) with maximum tumor shrinkage ≥75% (near-CR; n = 59), or PR with maximum tumor shrinkage <75% (other PR; n = 129), were characterized in terms of their baseline characteristics. The median duration of response was 43.7 mo (95% confidence interval [CI] 39.2-not estimable) for the CR group, 30.5 mo (95% CI 22.4-not estimable) for the near-CR group, and 17.2 mo (95% CI 12.5-21.4) for the other PR group. The 36-mo OS rates were consistently high in the CR (97%), near-CR (86%), and other PR (62%) groups. Robust objective response rates were observed across International Metastatic RCC Database Consortium favorable-risk (69%, 95% CI 60-78%), intermediate-risk (73%, 95% CI 67-79%), and poor-risk (70%, 95% CI 54-85%) subgroups. The robust response to L + P supports this combination as a standard-of-care first-line treatment for patients with aRCC. PATIENT SUMMARY: The CLEAR trial enrolled patients with advanced kidney cancer who had not previously received any treatment for their cancer. Here we report results for tumor shrinkage observed in the group that received lenvatinib plus pembrolizumab combination treatment during the trial. Shrinkage of target tumors with this combination was long-lasting and was observed in patients irrespective of their disease severity. This trial is registered on ClinicalTrials.gov as NCT02811861.
引用
- Motzer RJ, Choueiri TK, Hutson T, et al. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study. Eur Urol. 2024. PMID: 38582713. doi:10.1016/j.eururo.2024.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。